A recent study shows MedMira Reveal™ Rapid HIV-1 Antibody Test is the number one choice of hospitals in the USA (where over 80% of HIV testing is conducted) according to the 2003 study recently released by the U.S. CDC (Centers for Disease Control and Prevention) as part of the MPEP (Model Performance Evaluation Program) HIV Rapid Testing Practices Survey.

The majority of rapid HIV testing is conducted in clinical laboratories using serum or plasma, derived from human blood, while less than 5% of rapid HIV testing is conducted in Public Health facilities. When a rapid HIV test yields a positive result, serum or plasma is generally used for confirmation using traditional testing methods requiring a blood sample. Using a serum/plasma rapid test, like MedMira’s, reduces patient stress as it only requires one sample collection, unlike oral fluid tests. This preference was confirmed where 84% of clinical labs surveyed indicated a preference for serum or plasma.

MedMira recently launched its new FDA approved Reveal™ G2 Rapid HIV-1 Antibody Test (Reveal™ G2), the new generation rapid HIV-1 test for serum/plasma which features an on-board control line to minimize the number of control tests a laboratory must conduct, saving time and money. Reveal™ G2 was brought to the Point-Of-Care market based on market research with laboratory technicians and industry professionals to ensure the rapid test meets the specific needs of this market. Reveal™ G2 remains the fastest rapid test on the market at 3 minutes.

Other highlights of the survey show that the majority of respondents target delivery of results in less than one hour.